Continuous combined hormone replacement therapy and risk of endometrial cancer
Continuous combined hormone replacement therapy and risk of endometrial cancer
复制标题
DOI：
10.1067/mob.2000.108081
复制
发表时间：
2000-12-01
影响因子：
9.8
通讯作者：
Self, S
中科院分区：
文献类型：
--
作者：
Hill, DA;Weiss, NS;Self, S
目的：与从未接受过激素替代治疗的绝经后妇女相比，接受雌激素联合孕激素序贯激素替代治疗10 - 24小时较长时间可能会增加子宫内膜癌的风险。我们调查了每日使用雌激素和孕激素（持续联合激素替代疗法）是否可以降低任何过量的子宫内膜癌风险。研究设计：在华盛顿州进行的一项以人群为基础的研究获得了969名年龄在45岁至74岁之间的女性的访谈数据，这些女性在1985年至1991年或1994年至1995年期间被诊断患有子宫内膜癌，以及1325名年龄匹配的对照受试者，主要是通过随机数字拨号选择的。将仅接受持续联合激素替代治疗的妇女与仅接受另一种激素替代治疗方案或从未接受激素替代治疗的妇女进行比较。结果：持续联合激素替代治疗的妇女（n = 9例患者，n = 33名对照受试者）相对于从未接受激素替代治疗的妇女发生子宫内膜癌的风险为0.6(95%可信区间，0.3-1.3)；相对于接受含孕激素10 - 24毫克的激素替代的妇女，风险为0.4（95%可信区间为0.2-1.1）。大多数持续联合激素替代疗法的使用是短期的(
OBJECTIVE: Postmenopausal women who receive sequential hormone replacement therapy with estrogen Combined with progestogen for 10 to 24 dime for a prolonged period may have an elevated endometrial cancer risk relative to those who have never received hormone replacement therapy. We investigated whether daily use of estrogen and progestogen (continuous combined hormone replacement therapy) could diminish any excess endometrial cancer risk.STUDY DESIGN: A population-based study in Washington State obtained interview data from 969 women aged 45 to 74 years with endometrial cancer diagnosed during 1985 through 1991 or 1994 through 1995 and from 1325 age-matched control subjects selected primarily by random digit dialing. Women who had received only continuous combined hormone replacement therapy were compared with women who had only received another hormone replacement therapy regimen or who had never received hormone replacement-therapyRESULTS: The risk of endometrial cancer among users of continuous combined hormone replacement therapy (n = 9 case patients, n = 33 control subjects) relative to women who had never received hormone replacement therapy was 0.6 (95% confidence interval, 0.3-1.3); the risk relative to women who received hormone replacement that included progestogen for 10 to 24 dime was 0.4 (95% confidence interval, 0.2-1.1). Most Continuous combined hormone replacement therapy use was short-term (